Oxford BioTherapeutics

About:

Oxford BioTherapeutics develops medicines for cancer and companion diagnostics for selected antibody programs.

Website: http://www.oxfordbiotherapeutics.com

Top Investors: Silicon Valley Bank, Catapult Ventures, Oxford Capital, Calculus Capital, Oxford Finance LLC

Description:

Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP® (Oxford Genome Anatomy Project) platform. OGAP® is one of the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities.